Prime Medicine narrows Q2 2026 net loss to $42.1 million from $52.6 million
Prime Medicine reported second-quarter 2026 results, with its net loss narrowing to $42.1 million from $52.6 million a year earlier. Lower research and development and general and administrative spending drove the improvement, and the company also reported regulatory and arbitration updates for its pipeline. Cash, cash equivalents, investments and restricted cash fell to $108.8 million, and management says this funds operations into 2027.
Key points
- Net loss was $42.1 million, or $0.24 per share, for the quarter ended June 30, 2026, versus $52.6 million, or $0.41 per share, a year earlier.
- R&D expenses fell to $33.4 million from $41.4 million, and G&A expenses fell to $11.0 million from $13.1 million.
- Collaboration revenue from a related party was $1.15 million, compared with $1.12 million in the prior-year quarter.
- Cash and related balances were $108.8 million at June 30, 2026, down from $191.4 million at December 31, 2025.
The filing
Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.